TNFRSF13C and opsoclonus-myoclonus syndrome: Mean BAFF-R frequency was 94.5 ± 9.3% for untreated OMS (n = 6), 97.1 ± 5.4% for conventionally-treated OMS (n = 9), 90.1 ± 12.2% for multimodal immunotherapy (n = 13), and 96.9 ± 2.2% in controls, with no significant differences between groups (P = 0.45).